Past,Present,and Future of Continuous Glucose Monitors

International Diabetes Federation. IDF Diabetes Atlas, 10th ed. International Diabetes Federation: Brussels; 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition [Last accessed: January 31, 2022].

Sussman M , Benner J , Haller MJ , et al. Estimated lifetime economic burden of type 1 diabetes. Diabetes Technol Ther, 2020; 22(2):121–130; doi: 10.1089/dia.2019.0398

American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care, 2018; 41(5):917–928.

Link CL , McKinlay JB . Disparities in the prevalence of diabetes: Is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis, 2009; 19(3):288–292.

Garg SK , Kipnes M , Castorino K , et al. Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technol Ther, 2022; 24(6):373–380; doi: 10.1089/dia.2022.0011

Whooley S. FDA clears Abbott's next-gen FreeStyle Libre 3 14-day CGM. Drug Delivery Business News. May 31, 2022. Available from: https://www.drugdeliverybusiness.com/fda-abbott-next-gen-freestyle-libre-3-cgm [Last accessed: January 6, 2023].

Garg SK , Potts RO , Ackerman NR , et al. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care, 1999; 22(10):1708–1714; doi: 10.2337/diacare.22.10.1708

Tamada JA , Garg S , Jovanovic L , et al. Noninvasive glucose monitoring: Comprehensive clinical results. Cygnus Research Team. JAMA, 1999; 282(19):1839–1844; doi: 10.1001/jama.282.19.1839

Gross TM , Bode BW , Einhorn D , et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther, 2000; 2(1):49–56; doi: 10.1089/152091500316737

Garg S , Zisser H , Schwartz S , et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care, 2006; 29(1):44–50; doi: 10.2337/diacare.29.01.06.dc05-1686

Weinstein RL , Schwartz SL , Brazg RL , et al. Accuracy of the 5-day FreeStyle navigator continuous glucose monitoring system: Comparison with frequent laboratory reference measurements. Diabetes Care, 2007; 30(5):1125–1130; doi: 10.2337/dc06-1602

Garg SK. Emerging landscape of continuous glucose monitoring. Diabetes Technol Ther, 2021; 23(S3):S1–S4; doi: 10.1089/dia.2021.0271

Garg SK , Liljenquist D , Bode B , et al. Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable eversense continuous glucose monitoring system: The PROMISE Study. Diabetes Technol Ther, 2022; 24(2):84–92; doi: 10.1089/dia.2021.0182

Whooley S. Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor. Drug Delivery Business News. May 26, 2021. Available from: https://www.drugdeliverybusiness.com/medtronic-wins-ce-mark-for-smart-insulin-pen-cgm-system [Last accessed: February 16, 2023].

Carlson A , Sherr J , Shulman D , et al. Safety and glycemic outcomes during the MiniMed advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–189. PMID: 34694909

Wadwa RP , Laffel LM , Shah VN , et al. Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes. Diabetes Technol Ther, 2018; 20(6):395–402; doi: 10.1089/dia.2018.0150

Shah VN , Laffel LM , Wadwa RP , et al. Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther, 2018; 20(6):428–433.

Rickson M , Wright EE , Bindal A , Ghonim L . Advancements in diabetes technology are outpacing the evidence. Diabetes Technol Ther, 2023; 25(S3):S-35–S-41.

Wright EE , Subramanian S. Is continuous glucose monitoring a tool, an intervention, or both?. Diabetes Technol Ther, 2023; 25(S3):S-48–S-55.

Gavin II I JR, Bailey CJ . Continuous glucose monitoring impact and implications of real-world evidence: Past, present, and future. Diabetes Technol Ther, 2023; 25(S3):S-5–S-13.

Gagnum V , Stene LC , Jenssen TG , et al. Causes of death in childhood-onset Type 1 diabetes: Long-term follow-up. Diabet Med, 2017; 34(1):56–63; doi: 10.1111/dme.13114

Raghupathy P. Diabetic ketoacidosis in children and adolescents. Indian J Endocrinol Metab, 2015; 19(Suppl. 1) S55–S57.

Virdi N , Poon Y , Abaniel R , Bergenstal RM . Prevalence, cost, and burden of ketoacidosis. Diabetes Technol Ther, 2023; 25(S3):S-75–S-84.

Unger J , Franco DR . Practical application of continuous glucose monitoring in clinical practice: Case studies. Diabetes Technol Ther, 2023; 25(S3):S-21–S-34.

Ruedy KJ , Parkin CG , Riddlesworth TD , et al. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: Results from the DIAMOND trial. J Diabetes Sci Technol, 2017; 11(6):1138–1146.

Pratley RE , Kanapka LG , Rickels MR , et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial. JAMA, 2020; 323(23):2397–2406.

Munshi M , Slyne C , Davis D , et al. Use of technology in older adults with type 1 diabetes: Clinical characteristics and glycemic metrics. Diabetes Technol Ther, 2022; 24(1):1–9; doi: 10.1089/dia.2021.0246

McCarthy M , Grey M . Type 1 diabetes self-management from emerging adulthood through older adulthood. Diabetes Care, 2018; 41(8):1608–1614; doi: 10.2337/dc17-2597.dc17-2597

Weinstock RS , Xing D , Maahs DM , et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D Exchange clinic registry. J Clin Endocrinol Metab, 2013; 98(8):3411–3419; doi: 10.1210/jc.2013-1589.jc.2013-1589

Munshi MN. Continuous glucose monitoring use in older adults for optimal diabetes management. Diabetes Technol Ther, 2023; 25(S3):S-56–S-64.

National Diabetes Information Clearinghouse (NDIC). Sickle cell trait and other hemoglobinopathies and diabetes: important information for providers. Available from: https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/diabetes/sickle-cell-trait-hemoglobinopathies-diabetes [Last accessed: September 12, 2020].

Nielsen LR , Ekbom P , Damm P , et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care, 2005; 27(5):1200–1201.

Bry L , Chen PC , Sacks DB . Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem, 2001; 47(2):153–163.

Galindo RJ , Beck RW , Scioscia MF , et al. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev, 2020; 41(5):756–774; doi: 10.1210/endrev/bnaa017

Bergenstal RM , Gal RL , Connor CG , et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med, 2017; 167(2):95–102.

Shipman KE , Jawad M , Sullivan KM , et al. Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol, 2015; 52:687–692.

Wolffenbuttel BHR , Herman WH , Gross JL , et al. Ethnic differences in glycemicmarkers in patientswith type 2 diabetes. Diabetes Care, 2013; 36:2931–2936.

Dunn TC , Xu Y , Bergenstal RM , et al. Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator. Diabetes Technol Ther, 2023; 25(S3):S-65–S-74.

Centers for Disease Control and Prevention. Overweight & Obesity. Available from: https://www.cdc.gov/obesity/data/childhood.html [Last accessed: August 9, 2020].

Centers for Disease Control and Prevention (CDC)/National Diabetes Prevention Program. About Prediabetes and Type 2 Diabetes. December 27, 2022. Available from: https://www.cdc.gov/diabetes/prevention/about-prediabetes.html [Last accessed: January 6, 2023].

Yokota N , Miyakoshi T , Sato Y , et al. Predictive models for conversion of prediabetes to diabetes. J Diabetes Complications, 2017; 31(8):1266–1271; doi: 10.1016/j.jdiacomp.2017.01.005

Miller E , Polonsky WH , Miller K. What role might there be for continuous glucose monitoring in the assessment of diabetes risk?. Diabetes Technol Ther, 2023; 25(S3):S-14–S-20.

Midyett LK. One size fits all versus individualized medicine in type 1 diabetes management. Diabetes Technol Ther, 2023; 25(S3):S-42–S-47.

Garg SK , Rodriguez E , Almurashi AM . Continuous Glucose Monitors/Hybrid Closed Loop Systems. Medscape, 2022. Available from: https://emedicine.medscape.com/article/2500145-overview [Last accessed: September 06, 2022].

Almurashi AM , Rodriguez E , Garg SK . Emerging diabetes technologies: Continuous glucose monitors/artificial pancreases. J Indian Inst Sci, 2023; doi: 10.1007/s41745-022-0348-3

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.

Battelino T , Alexander CM , Amiel SA , et al. Continuous glucose monitoring and CGM metrics for clinical trials: An international consensus. Lancet Diabetes Endocrinol, 2022; 11(1):45–57, 2023. PMID: 36493795

Van der Linden J , Welsh JB , Hirsch I , et al. Real-time continuous glucose monitoring during the coronavirus disease 2019 pandemic and its impact on time in range. Diabetes Technol Ther, 2021; 23(S1):S1–S7.

Peters AL , Garg SK . The silver lining to COVID-19: Avoiding DKA admissions with telehealth. Diabetes Technol Ther, 2020; 22(6):449–453.